Michel Azizi

List of Publications by Year in descending order

107 papers	16,359 citations	66343 42 h-index	27406 106 g-index
116 all docs	116 docs citations	116 times ranked	17061 citing authors

#	Article	IF	Citations
1	Current progress in clinical, molecular, and genetic aspects of adult fibromuscular dysplasia. Cardiovascular Research, 2022, 118, 65-83.	3.8	14
2	Drug-resistant hypertension in primary aldosteronism patients undergoing adrenal vein sampling: the AVIS-2-RH study. European Journal of Preventive Cardiology, 2022, 29, e85-e93.	1.8	19
3	Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO study. Journal of Human Hypertension, 2022, 36, 629-639.	2.2	14
4	Plasma renin and aldosterone concentrations related to endovascular ultrasound renal denervation in the RADIANCE-HTN SOLO trial. Journal of Hypertension, 2022, 40, 221-228.	0.5	6
5	Renal Artery Variations in Patients With Mild-to-Moderate Hypertension From the RADIANCE-HTN SOLO Trial. Cardiovascular Revascularization Medicine, 2022, 39, 58-65.	0.8	3
6	Nonadherence in Hypertension: How to Develop and Implement Chemical Adherence Testing. Hypertension, 2022, 79, 12-23.	2.7	51
7	Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium. Circulation, 2022, 145, 847-863.	1.6	28
8	Use of traditional medicine and control of hypertension in 12 African countries. BMJ Global Health, 2022, 7, e008138.	4.7	4
9	Aldosterone receptor antagonists. Annales D'Endocrinologie, 2021, 82, 179-181.	1.4	7
10	Rare loss-of-function mutations of PTGIR are enriched in fibromuscular dysplasia. Cardiovascular Research, 2021, 117, 1154-1165.	3.8	20
11	Ambulatory Blood Pressure Monitoring to Predict Response to Renal Denervation. Hypertension, 2021, 77, 529-536.	2.7	15
12	Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	13.7	197
13	Beyond Atherosclerosis and Fibromuscular Dysplasia: Rare Causes of Renovascular Hypertension. Hypertension, 2021, 78, 898-911.	2.7	12
14	SPARTE Study: Normalization of Arterial Stiffness and Cardiovascular Events in Patients With Hypertension at Medium to Very High Risk. Hypertension, 2021, 78, 983-995.	2.7	65
15	Cardiometabolic Disorders and the Risk of Critical COVID-19 as Compared to Influenza Pneumonia. Journal of Clinical Medicine, 2021, 10, 4618.	2.4	4
16	Genetic investigation of fibromuscular dysplasia identifies risk loci and shared genetics with common cardiovascular diseases. Nature Communications, 2021, 12, 6031.	12.8	34
17	Blood pressure-lowering medicines implemented in 12 African countries: the cross-sectional multination EIGHT study. BMJ Open, 2021, 11, e049632.	1.9	2
18	Aldosterone-Related Myocardial Extracellular Matrix Expansion in Hypertension in Humans. JACC: Cardiovascular Imaging, 2020, 13, 2149-2159.	5.3	23

#	Article	IF	Citations
19	12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation. JACC: Cardiovascular Interventions, 2020, 13, 2922-2933.	2.9	47
20	Home blood pressure monitoring and e-Health: investigation of patientsâ€™ experience with the Hy-Result system. Blood Pressure Monitoring, 2020, 25, 155-161.	0.8	9
21	Sequential nephron blockade with combined diuretics improves diastolic function in patients with resistant hypertension. ESC Heart Failure, 2020, 7, 2561-2571.	3.1	5
22	Antihypertensive strategies and hypertension control in Sub-Saharan Africa. European Journal of Preventive Cardiology, 2020, 28, e21-e25.	1.8	3
23	Drug-Induced Hypertension. Updates in Hypertension and Cardiovascular Protection, 2020, , 159-166.	0.1	0
24	Device-based therapies for arterial hypertension. Nature Reviews Cardiology, 2020, 17, 614-628.	13.7	77
25	Hypertension, the reninâ€“angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovascular Research, 2020, 116, 1688-1699.	3.8	282
26	Poor adherence to medication and salt restriction as a barrier to reaching blood pressure control in patients with hypertension: Cross-sectional study from 12 sub-Saharan countries. Archives of Cardiovascular Diseases, 2020, 113, 433-442.	1.6	15
27	Using social media to recruit study participants for a randomized trial for hypertension. European Heart Journal Digital Health, 2020, 1, 71-74.	1.7	3
28	Resistant Hypertension and Atherosclerotic Renal Artery Stenosis. Hypertension, 2019, 74, 1516-1523.	2.7	27
29	Emerging Drug Classes and Their Potential Use in Hypertension. Hypertension, 2019, 74, 1075-1083.	2.7	46
30	Clinic Versus Ambulatory Blood Pressure in Resistant Hypertension: Impact of Antihypertensive Medication Nonadherence. Hypertension, 2019, 74, 1096-1103.	2.7	10
31	Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control After Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial. Circulation, 2019, 139, 2542-2553.	1.6	97
32	Clinical characteristics, antihypertensive medication use and blood pressure control among patients with treatment-resistant hypertension. Journal of Hypertension, 2019, 37, 2216-2224.	0.5	7
33	P-glycoprotein influences urinary excretion of aldosterone in healthy individuals. Journal of Hypertension, 2019, 37, 2225-2231.	0.5	6
34	First International Consensus on the diagnosis and management of fibromuscular dysplasia. Vascular Medicine, 2019, 24, 164-189.	1.5	232
35	Usefulness of Magnetic Resonance Imaging in the Diagnosis of Juxtaglomerular Cell Tumors: A Report of 10 Cases and Review of the Literature. American Journal of Kidney Diseases, 2019, 73, 566-571.	1.9	13
36	SAT-012 Urinary Aldosterone Assay Using LC-MS/MS Could Improve Primary Aldosteronism Screening. Journal of the Endocrine Society, 2019, 3, .	0.2	1

#	Article	IF	Citations
37	Cause of renal infarction. Journal of Hypertension, 2018, 36, 634-640.	0.5	31
38	How to perform a cost-effectiveness analysis with surrogate endpoint: renal denervation in patients with resistant hypertension (DENERHTN) trial as an example. Blood Pressure, 2018, 27, 66-72.	1.5	13
39	A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: The RADIANCE-HTN and REQUIRE clinical study designs. American Heart Journal, 2018, 195, 115-129.	2.7	64
40	2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Journal of Hypertension, 2018, 36, 2284-2309.	0.5	689
41	2018 Practice guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Blood Pressure, 2018, 27, 314-340.	1.5	254
42	2018 ESC/ESH Guidelines for the management of arterial hypertension. Journal of Hypertension, 2018, 36, 1953-2041.	0.5	2,129
43	Renal denervation in hypertension: Towards a true revival?. Archives of Cardiovascular Diseases, 2018, 111, 541-544.	1.6	1
44	Resistant Hypertension. , 2018, , 398-408.		1
45	European Society of Hypertension position paper on renal denervation 2018. Journal of Hypertension, 2018, 36, 2042-2048.	0.5	39
46	Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet, The, 2018, 391, 2335-2345.	13.7	526
47	2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, 2018, 39, 3021-3104.	2.2	6,826
48	Will SPYRAL HTN-ON MED change my practice? SPYRAL HTN-ON MED: a prospective, randomised, sham-controlled trial on renal denervation in the presence of antihypertensive medications. EuroIntervention, 2018, 14, e598-e602.	3.2	3
49	Will SPYRAL HTN-OFF MED change my practice? SPYRAL HTN-OFF MED: a prospective, randomised, sham-controlled trial on renal denervation in the absence of antihypertensive medications. EuroIntervention, 2018, 14, e603-e606.	3.2	2
50	Drug Adherence in Resistant Hypertension. Updates in Hypertension and Cardiovascular Protection, 2018, , 185-197.	0.1	0
51	La recherche en hypertension artÃ©rielle en France. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 1571-1579.	0.0	0
52	Twenty-Four-Hour Blood Pressure Monitoring to Predict and Assess Impact of Renal Denervation. Hypertension, 2017, 69, 494-500.	2.7	34
53	Transcriptome Analysis of Human Reninomas as an Approach to Understanding Juxtaglomerular Cell Biology. Hypertension, 2017, 69, 1145-1155.	2.7	10
54	Drug adherence in hypertension. Journal of Hypertension, 2017, 35, 1133-1144.	0.5	79

#	Article	IF	Citations
55	Impaired atrioventricular transport in patients with transposition of the great arteries palliated by atrial switch and preserved systolic right ventricular function: A magnetic resonance imaging study. Congenital Heart Disease, 2017, 12, 458-466.	0.2	10
56	Abdominal Aortic Calcifications Influences the Systemic and Renal Hemodynamic Response to Renal Denervation in the DENERHTN (Renal Denervation for Hypertension) Trial. Journal of the American Heart Association, 2017, 6, .	3.7	25
57	High Prevalence of Multiple Arterial Bed Lesions in Patients With Fibromuscular Dysplasia. Hypertension, 2017, 70, 652-658.	2.7	115
58	Detecting Nonadherence to Antihypertensive Treatment. Hypertension, 2017, 70, 257-258.	2.7	3
59	Catheter-based renal denervation for treatment of hypertension. Lancet, The, 2017, 390, 2124-2126.	13.7	10
60	Adherence to Antihypertensive Treatment and the Blood Pressureâ€“Lowering Effects of Renal Denervation in the Renal Denervation for Hypertension (DENERHTN) Trial. Circulation, 2016, 134, 847-857.	1.6	144
61	Evaluation of Adherence Should Become an Integral Part of Assessment of Patients With Apparently Treatment-Resistant Hypertension. Hypertension, 2016, 68, 297-306.	2.7	147
62	Renal Denervation for Treatment of Hypertension: a Second Start and New Challenges. Current Hypertension Reports, 2016, 18, 6.	3.5	32
63	PHACTR1 Is a Genetic Susceptibility Locus for Fibromuscular Dysplasia Supporting Its Complex Genetic Pattern of Inheritance. PLoS Genetics, 2016, 12, e1006367.	3.5	146
64	True antihypertensive efficacy of sequential nephron blockade in patients with resistant hypertension and confirmed medication adherence. Journal of Hypertension, 2015, 33, 2526-2533.	0.5	28
65	Design Considerations for Clinical Trials of Autonomic Modulation Therapies Targeting Hypertension and Heart Failure. Hypertension, 2015, 65, 5-15.	2.7	27
66	Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet, The, 2015, 385, 1957-1965.	13.7	453
67	Design of renal denervation studies not confounded by antihypertensive drugs. Journal of the American Society of Hypertension, 2015, 9, 337-340.	2.3	5
68	Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension. Blood Pressure, 2015, 24, 263-274.	1.5	65
69	The double challenge of resistant hypertension and chronic kidney disease. Lancet, The, 2015, 386, 1588-1598.	13.7	147
70	Renal denervation for resistant hypertension â€“ Authors' reply. Lancet, The, 2015, 386, 1240.	13.7	2
71	Eligibility for Renal Denervation: Anatomical Classification and Results in Essential Resistant Hypertension. CardioVascular and Interventional Radiology, 2015, 38, 79-87.	2.0	20
72	Renal denervation with a percutaneous bipolar radiofrequency balloon catheter in patients with resistant hypertension: 6-month results from the REDUCE-HTN clinical study. EuroIntervention, 2015, 10, 1213-1220.	3.2	56

#	Article	IF	Citations
73	European consensus on the diagnosis and management of fibromuscular dysplasia. Journal of Hypertension, 2014, 32, 1367-1378.	0.5	154
74	Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual reninâ€“angiotensin blockade for left ventricular mass regression in patients with resistant hypertension. Journal of Hypertension, 2014, 32, 2038-2044.	0.5	14
75	Renal artery stenosis following renal denervation. Journal of Hypertension, 2014, 32, 2101-2105.	0.5	26
76	Renin Inhibitors and Cardiovascular and Renal Protection: An Endless Quest?. Cardiovascular Drugs and Therapy, 2013, 27, 145-153.	2.6	24
77	Effect of Contrasted Sodium Diets on the Pharmacokinetics and Pharmacodynamic Effects of Reninâ€“Angiotensin System Blockers. Hypertension, 2013, 61, 1239-1245.	2.7	8
78	Association of Smoking With Phenotype at Diagnosis and Vascular Interventions in Patients With Renal Artery Fibromuscular Dysplasia. Hypertension, 2013, 61, 1227-1232.	2.7	57
79	Association Between 2 Angiographic Subtypes of Renal Artery Fibromuscular Dysplasia and Clinical Characteristics. Circulation, 2012, 126, 3062-3069.	1.6	110
80	Sequential nephron blockade versus sequential reninâ€“angiotensin system blockade in resistant hypertension. Journal of Hypertension, 2012, 30, 1656-1664.	0.5	111
81	Effets vasculaires et rÃ©naux des mÃ©dicaments anti-angiogÃ©niques : recommandations franÃ§aises pour la pratique. Sang Thrombose Vaisseaux, 2009, 21, 151-166.	0.1	1
82	Managing cardiovascular and renal risk: the potential of direct renin inhibition. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2009, 10, 65-76.	1.7	53
83	Salvage Therapy with Bevacizumabâ€“Sunitinib Combination after Failure of Sunitinib Alone for Metastatic Renal Cell Carcinoma: A Case Series. European Urology, 2009, 56, 207-211.	1.9	20
84	Direct renin inhibition: clinical pharmacology. Journal of Molecular Medicine, 2008, 86, 647-654.	3.9	18
85	RENIN INHIBITION WITH ALISKIREN. Clinical and Experimental Pharmacology and Physiology, 2008, 35, 426-430.	1.9	15
86	Highlights from International Congress. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 91-104.	2.2	0
87	Reciprocal Regulation of Plasma Apelin and Vasopressin by Osmotic Stimuli. Journal of the American Society of Nephrology: JASN, 2008, 19, 1015-1024.	6.1	121
88	Home Blood-Pressure Monitoring in Patients Receiving Sunitinib. New England Journal of Medicine, 2008, 358, 95-97.	27.0	181
89	Hormonal and Hemodynamic Effects of Aliskiren and Valsartan and Their Combination in Sodium-Replete Normotensive Individuals. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 947-955.	4.5	57
90	The difficult conception, birth and delivery of a renin inhibitor: controversies around aliskiren. Journal of Hypertension, 2007, 25, 1775-1782.	0.5	32

#	Article	IF	Citations
91	Aliskiren, an Orally Effective Renin Inhibitor, Provides Antihypertensive Efficacy Alone and in Combination With Valsartan. American Journal of Hypertension, 2007, 20, 11-20.	2.0	215
92	Rationale for Combining Blockers of the Renin-Angiotensin System. Seminars in Nephrology, 2007, 27, 544-554.	1.6	10
93	Renin inhibition with aliskiren: where are we now, and where are we going?. Journal of Hypertension, 2006, 24, 243-256.	0.5	229
94	Conformational changes in prorenin during renin inhibition in vitro and in vivo. Journal of Hypertension, 2006, 24, 529-534.	0.5	37
95	Renin inhibition. Current Opinion in Nephrology and Hypertension, 2006, 15, 505-510.	2.0	21
96	Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans. Clinical Pharmacology and Therapeutics, 2006, 79, 49-61.	4.7	20
97	Combined Blockade of the Renin-Angiotensin System With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Antagonists. Circulation, 2004, 109, 2492-2499.	1.6	184
98	Integrating Drug Pharmacokinetics for Phenotyping Individual Renin Response to Angiotensin II Blockade in Humans. Hypertension, 2004, 43, 785-790.	2.7	38
99	Pharmacologic Demonstration of the Synergistic Effects of a Combination of the Renin Inhibitor Aliskiren and the AT1 Receptor Antagonist Valsartan on the Angiotensin IIâ€“Renin Feedback Interruption. Journal of the American Society of Nephrology: JASN, 2004, 15, 3126-3133.	6.1	234
100	Renin???angiotensin system blockade. Journal of Hypertension, 2004, 22, 459-462.	0.5	1
101	Haemodynamic effects of dual blockade of the renin???angiotensin system in spontaneously hypertensive rats. Journal of Hypertension, 2004, 22, 619-627.	0.5	26
102	Dual renin???angiotensin system blockade restores blood pressure???renin dependency in individuals with low renin concentrations. Journal of Hypertension, 2003, 21, 1887-1895.	0.5	17
103	Physiologic Consequences of Vasopeptidase Inhibition in Humans: Effect of Sodium Intake. Journal of the American Society of Nephrology: JASN, 2002, 13, 2454-2463.	6.1	20
104	Pilot study of combined blockade of the reninâ€“angiotensin system in essential hypertensive patients. Journal of Hypertension, 2000, 18, 1139-1147.	0.5	67
105	Pharmacokinetic-pharmacodynamic interactions of candesartan cilexetil and losartan. Journal of Hypertension, 1999, 17, 561-568.	0.5	19
106	Additive Effects of Losartan and Enalapril on Blood Pressure and Plasma Active Renin. Hypertension, 1997, 29, 634-640.	2.7	99
107	Additive Effects of Combined Angiotensin-Converting Enzyme Inhibition and Angiotensin II Antagonism on Blood Pressure and Renin Release in Sodium-Depleted Normotensives. Circulation, 1995, 92, 825-834.	1.6	183